ONCOC4, INC.
ROCKVILLE, MD · Founded 2020 · CIK 0001839078 · Biotech · Private
ONC-392, a novel anti-CTLA-4 monoclonal antibody that preserves immune checkpoint function while selectively depleting regulatory T cells in tumors
oncoc4.com →- Grants
- $2.0M
- 2 awards
- Sector median: 1
- Raised
- $50M
- 1 Form D · Jan 2021
- 69 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 29
- 2 granted · 27 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $50,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | $1,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3269 | Outer Biosciences Inc | — | $23M |
| 3270 | Prelenia | — | — |
| 3271 | Ophysio Inc. | — | — |
| 3272 | ONCOC4, INC. | — | $50M |
| 3273 | CLUE GENETICS INC. | — | — |
| 3274 | Ibex Investment Holdings LLC | — | $5.0M |
| 3275 | Lucidicor Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Martin DevenportExecutive Officer
- Michael FlaschenDirector
- Yang LiuDirector · Executive Officer
Patents
- Composition and Method for Synthesizing Pegylated Uricase-Drug Conjugates to Mitigate Anti-Drug Antibody and Their Therapeutic Useapplication
- ANTI-CTLA-4 Antibody Dosing Regimensapplication
- Use Of ANTI-CTLA-4 Antibodies For Treating Adenoid Cystic Carcinomaapplication
- Method Of Abrogating Anti-drug Antibody Formation, And Drug Conjugates For Use Thereinapplication
- Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereofgranted
- Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereofgranted
- Uses Of Hypoxia-inducible Factor Inhibitorsapplication
- Ph-sensitive ANTI-CTLA-4 Antibodies And Uses Thereofapplication
- Combinations Of ANTI-CTLA-4 Antibodies And ANTI-PD-1 Antibodies And Therapeutic Uses Thereofapplication
- Anti-vegf And PD-1 Bispecifc Antibodies And Uses Thereofapplication
- ANTI-CD24 Antibody Drug Conjugates And Uses Thereofapplication
- ANTI-CD24/ANTI-CD3 Bispecific Binding Proteins And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.